Literature DB >> 11020293

Novel cannabinol probes for CB1 and CB2 cannabinoid receptors.

A Mahadevan1, C Siegel, B R Martin, M E Abood, I Beletskaya, R K Razdan.   

Abstract

The observation that the phenolic hydroxyl of THCs was important for binding to the CB1 receptor but not as critical for binding to the CB2 receptor prompted us to extend this finding to the cannabinol (CBN) series. To study the SAR of CBN analogues, CBN derivatives with substitution at the C-1, C-3, and C-9 positions were chosen since these positions have played a key role in the SAR of THCs. CBN-3-(1',1'-dimethylheptyl) analogues were prepared by sulfur dehydrogenation of Delta(8)-THC-3-(1',1'-dimethylheptyl) analogues. 9-Substituted CBN analogues were prepared by the standard sulfur dehydrogenation of 9-substituted Delta(8)-THC analogues (Scheme 1), which in turn were prepared following our previous procedure using selenium dioxide oxidation of the corresponding Delta(8)-THCs followed by sodium chlorite oxidation to give the 9-carboxy-Delta(8)-THC derivatives. 11-Hydroxy-CBN analogues were prepared from the corresponding 9-carbomethoxy-CBN analogues by reduction with LiAlH(4). Deoxy-CBN analogue 14 was prepared from the corresponding Delta(8)-THC analogue 11 by conversion of the phenolic hydroxyl to the phosphate derivative 12, followed by lithium ammonia reduction to provide the deoxy-Delta(8)-THC analogue 13, which in turn was dehydrogenated with sulfur to provide the deoxy-CBN analogue 14 (Scheme 2). The various analogues were assayed for binding both to the brain and the peripheral cannabinoid receptors (CB1 and CB2). We have found that the binding profile differs widely between the CBN and the THC series. Specifically, in the CBN series the removal of the phenolic hydroxyl decreases binding affinity to both the CB1 and CB2 receptors, whereas in the THC series, CB1 affinity is selectively reduced. Thus, in the CBN series, the selectivity of binding observed with the removal of the hydroxy group is decreased severalfold as compared to what occurs in the THC series. Generally, high affinity for the CB2 receptor was found in analogues when the phenolic hydroxyl was present. The 3-(1', 1'-dimethylheptyl) derivatives were found to have much higher affinities than the CBN analogues, which is in complete agreement with previously reported work by Rhee et al.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11020293     DOI: 10.1021/jm0001572

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive properties.

Authors:  Jose Cumella; Laura Hernández-Folgado; Rocio Girón; Eva Sánchez; Paula Morales; Dow P Hurst; Maria Gómez-Cañas; Maria Gómez-Ruiz; Diana C G A Pinto; Pilar Goya; Patricia H Reggio; María Isabel Martin; Javier Fernández-Ruiz; Artur M S Silva; Nadine Jagerovic
Journal:  ChemMedChem       Date:  2012-02-02       Impact factor: 3.466

2.  Novel adamantyl cannabinoids as CB1 receptor probes.

Authors:  Ganesh A Thakur; Shama Bajaj; Carol Paronis; Yan Peng; Anna L Bowman; Lawrence S Barak; Marc G Caron; Demon Parrish; Jeffrey R Deschamps; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2013-05-14       Impact factor: 7.446

3.  Synthesis of (-)-Delta9-trans-tetrahydrocannabinol: stereocontrol via Mo-catalyzed asymmetric allylic alkylation reaction.

Authors:  Barry M Trost; Kalindi Dogra
Journal:  Org Lett       Date:  2007-02-01       Impact factor: 6.005

Review 4.  Cannabinoid Signaling and Neuroinflammatory Diseases: A Melting pot for the Regulation of Brain Immune Responses.

Authors:  Valerio Chiurchiù; Alessandro Leuti; Mauro Maccarrone
Journal:  J Neuroimmune Pharmacol       Date:  2015-01-20       Impact factor: 4.147

Review 5.  Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation.

Authors:  Slava Rom; Yuri Persidsky
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-08       Impact factor: 4.147

Review 6.  Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC.

Authors:  Jackson M J Oultram; Joseph L Pegler; Timothy A Bowser; Luke J Ney; Andrew L Eamens; Christopher P L Grof
Journal:  Biomedicines       Date:  2021-02-26

Review 7.  Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses.

Authors:  Kenneth B Walsh; Amanda E McKinney; Andrea E Holmes
Journal:  Front Pharmacol       Date:  2021-11-29       Impact factor: 5.810

8.  SARs for the Antiparasitic Plant Metabolite Pulchrol. 3. Combinations of New Substituents in A/B-Rings and A/C-Rings.

Authors:  Paola Terrazas; Efrain Salamanca; Marcelo Dávila; Sophie Manner; Alberto Gimenez; Olov Sterner
Journal:  Molecules       Date:  2021-06-28       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.